NCT07172789Recruiting
Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5)
Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5): a Prospective, Randomized, Open Label, Blinded-end Point, Multi-center Study
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
Recent studies suggest that head-down positioning (HDP) intervention may improve outcomes in ischemic stroke. In the era of reperfusion therapy, a key protective strategy is to administer neuroprotective interventions before recanalization to reduce the loss of the ischemic penumbra, thereby salvaging more penumbral tissue after revascularization and ultimately improving clinical outcomes. Based on this concept, and considering the neuroprotective effects of HDP, the investigators hypothesize that HDP intervention prior to endovascular therapy (EVT) in patients with large vessel occlusion could improve clinical outcomes. This hypothesis is further supported by a recent clinical study (NCT03728738), which demonstrated that compared to a sitting up position (30°), a flat supine position (0°) before EVT significantly reduced the incidence of neurological deterioration prior to the procedure. Building on the above rationale, this trial aims to investigate the efficacy and safety of HDP intervention prior to EVT in patients with large vessel occlusion.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 210 (estimated)
- First submitted
- 2 Sept 2025
- Start date
- 2 Sept 2025
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- General Hospital of Shenyang Military Region
- Diseases
- Stroke
- NCT number
- NCT07172789
What you commit to
- Study type: Interventional
- Planned participants: 210
- From 2 Sept 2025 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;
- Severe hypertension before randomization (systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg);
- Cardiac insufficiency (NYHA Class ≥II);
- The estimated life expectancy is less than 6 months due to other serious diseases;
- Other conditions unsuitable for this clinical study assessed by researcher.
Lab values
- Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
Other
- Pregnancy, plan to get pregnant or during lactation;
- Patients at significant risk of aspiration (e.g., obvious nausea and vomiting);
Who the study is looking for
- Age ≥ 18 years;
- Patients with acute large vessel occlusion scheduled for endovascular thrombectomy within 24 hours of symptom onset;
- Baseline National Institute of Health Stroke Scale (NIHSS) ≥ 6;
- Expected waiting time from randomization to femoral artery puncture is more than 30 minutes;
- ASPECTS/pc-ASPECTS score ≥ 6 on baseline non-contrast CT or DWI;
- Modified Rankin Scale score before stroke onset ≤ 1;
- Signed informed consent by patient or their legally authorized representative.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hui-Sheng Chen Coordinator of this site? Confirm its status | Shenyang | China | Recruiting |
Related publications
- Head Down Position Before Endovascular Treatment for Large Vessel Occlusion: Clinical Trial Design.J Am Heart Assoc · 2026 · PMID 41778610
This page is information, not medical advice. Discuss any trial with your doctor.